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Methods
Morphological and functional cardiac changes in TAVI follow-up:
evaluation through transthoracic echocardiography
Type of Study - Descriptive and retrospective study.
Study population - 10 patients, between 63 and 85 years old, submitted to
TAVI were evaluated by transthoracic echocardiography.
Variables - Sex, age, body mass index, type 2 diabetes mellitus,
dyslipidemia, hypertension, smoking, family history of coronary disease,
hormonal risk factors and EuroSCORE.
Echocardiographic variables: perivalvular regurgitation, maximum velocity
and gradient, left ventricular end-diastolic and end-systolic volume, ejection
fraction, left ventricular mass index and left atrium diameter.
Inclusion Criteria - Patients refused for conventional surgery, Aortic valve:
model Edward Sapiens and evaluation made by transthoracic
echocardiogram between 24h to 72h and from 1 to 14 months after the
procedure (from January 2014 to April 2016).
Exclusion criteria - Bad acoustic window, incomplete protocol and presence
of known cardiopulmonary disease: acute myocardial infarction,
hypertrophic cardiomyopathy and dilated cardiomyopathy.
Statistical analysis - Descriptive statistics, Shapiro-Wilk test, Wilcoxon's test
and McNemar test. The results were considered statistically significant
when p value < 0.05.
Protocol - According to the recommendations of the American Society of
Echocardiography (2010).5 Two transthoracic echocardiograms were
evaluated: the first was performed 24h to 72h after TAVI procedure and the
2nd from 1 to 14 months after the procedure. All measurements were made
off line by a single operator to minimize variability. Phillips CX50®
ultrasound systems was used.
Objective
To describe and compare morphological and functional cardiac changes,
through transthoracic echocardiography, in the follow-up after TAVI.
Aortic Stenosis is a valvular disease with increasing prevalence. The most common etiology of aortic stenosis is degenerative calcification of the leaflets due to
lipid accumulation, fibrosis and inflammation, usually present in older individuals, and has bad prognosis when becomes symptomatic. The replacement of the
aortic valve is the first surgical therapeutic option for severe aortic stenosis however, 30 to 40% of patients cannot accomplish by contraindications.
Transcatheter aortic valve implantation (TAVI) is a treatment option for patients who cannot undergo surgical valve replacement. 1,2,3,4
Background
Conclusions
Transcatheter valve aortic implantation is a relatively new procedure for aortic
stenosis treatment, with morphological and functional changes in the heart.3
It was registered a significant increase in maximum velocity and gradient from the
first to the second echocardiogram.
Left ventricular mass index decreased in average 15.71 g/m2, and from a clinical
perspective can have an impact in the patient’s prognostic.
Results
10 patients were studied with an average age of 76 years old, 60% male, an
average body mass index of 25.42Kg/m2.
Regarding the risk factors, 60% of the patients had dyslipidemia, 70%
hypertension, 40% type 2 diabetes mellitus and 10% family history of coronary
disease. No patient presented hormonal risk factors or smoking habits. On
average, patients had a EuroSCORE of 2.96, and approximately 2 simultaneous
risk factors.
It was registered a significant increase in maximum velocity and gradient
(p=0.004 and p=0.010, respectively) from the first to the second
echocardiogram. There weren’t significant differences in left ventricle ejection
fraction, end-diastolic and end-systolic volumes and in left atrium diameter.
Left ventricle mass index decreased comparing to the first echocardiogram
(from 157.92 to 142.28 g/m2), however, this difference wasn’t statistically
relevant. The prevalence of regurgitation (80%) was unchanged between
evaluations.
Fig. 2 – Echocardiographic variables – results
1st Echo Evaluation
Mean ± SD or %
2nd Echo Evaluation
Mean ± SD or %
Difference from 
2nd to 1st evaluation
Mean ± SD 
p value
Maximum velocity
(m/s) 
1.88 ± 0.34 2.36 ± 0.48 0.47 ± 0.40 0.004
Maximum gradient 
(mmHg) 
14.59 ± 5.03 23.00 ± 9.87 8.42 ± 8.24 0.010
Ejection fraction (%) 59.59 ± 5.85 59.45 ± 9.94 -0.13 ± 8.56 0.963
End-diastolic volume
(ml) 
98.72 ± 21.85 101.25 ± 43.19 3.18 ± 45.48 0.284
End-systolic volume 
(ml) 
40.46 ± 12.91 42.36 ± 24.50 1.90 ± 25.91 0.575
Left ventricular mass 
index (gr/m2) 
157.99 ± 38.77 142.28 ± 28.01 -15.71 ± 27.29 0.102
Left atrium diameter 
(mm) 
63.69 ± 13.17 64.21 ± 11.01 0.52 ± 7.34 0.827
Aortic perivalvular
regurgitation  
80% 80% - 1.000
Regurgitation severity  
Mild – 75%
Moderate – 25%
Mild – 62.5%
Moderate – 37.5%
- -
Fig.1 - Edwards SAPIEN® transcatheter aortic valve replacement - Edwards Lifesciences LLC6
